CDB-2914, a novel selective progesterone receptor modulator, differentially regulates endometrial gene expression in the proliferative phase of the menstrual cycle

Abstract

In response to ovarian steroids, human uterine endometrium dynamically alters its composition throughout the menstrual cycle. As part of a blinded, randomized, placebo-controlled trial, CDB-2914 (CDB), a selective progesterone modulator, was used to treat women with symptomatic uterine leiomyomas over a 90 day period. CDB induced amenorrhea in all treated patients. The objective of this study was to evaluate effects of CDB and placebo on the endometrial molecular environment and to identify possible mechanisms responsible for differential actions.